B -- RESOURCE FOR THE COLLECTION AND EVALUATION OF HUMAN TISSUES AND CELLS FROM DONORS WITH AN EPIDEMIOLOGY PROFILE

Notice Date

December 21, 2000

Contracting Office

National Cancer Institute, Research Contracts Branch, TBS, 6120 Executive Blvd, EPS/Rm 603 Bethesda, MD 20892-7220

ZIP Code

20892-7220

Solicitation Number

N02-BC-17011-48

Point of Contact

John R. Manouelian, Contract Specialist, 301-496-8620

E-Mail Address

John R. Manouelian, Contract Specialist, 301-496-8620 (manouelj@mail.nih.gov)

Description

ELECTRONIC RFP ANNOUNCEMENT, POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. The Laboratory of Human Carcinogenesis (LHC), Division of Basic Sciences (DBS), National Cancer Institute (NCI), National Institutes of Health (NIH), is recompeting a four-year tissue collection contract. The Contractor for this procurement will obtain (via informed consent) and characterize (histo-pathologically) normal-appearing and neoplastic bronchial, pulmonary, esophageal, intestinal, colonic, breast, pancreatic and hepatic tissues and cells, as well as other biological specimens (including pleural effusions, urine, and blood and its components) at the time of surgery for cancer or non-cancer conditions, and at immediate autopsy of non-cancer donors from organ transplant units, shock-trauma sources, or routine autopsy from medical examiner cases. As well, the Contractor will prepare epidemiological profiles on all donors willing to provide personal information from current medical records and historical, social, occupational and family health information, to complete an epidemiological questionnaire. The incumbent Contractor is The University of Maryland at Baltimore (Contract No. N02-BC-71006), which is scheduled to expire on March 30, 2001. The LHC utilizes the human tissues and cells for in-vitro carcinogenesis, case-control, and case-series studies, which have previously and will in the future allow the LHC to contribute to the general advancement of in-vitro methods for investigating: (a) molecular and genetic components of malignant human cells; (b) normal cell phenotypes modified by the transfection of genes or exposure to chemical carcinogens; (c) cellular phenotypes differentiating the mutagen sensitivity between cancer and non-cancer patients; and (d) detection and measure of cellular markers associated with the initiation and prognosis of cancer. The NCI shall consider proposals from all responsible sources. However, Offerors must demonstrate in their technical proposal, their ability to facilitate delivery of the non-frozen viable tissues to the NCI in Bethesda, Maryland, within two hours from receipt of pathology and within four hours from receipt of surgery, as a mandatory qualification criteria of this solicitation. Failure to demonstrate this element at the time of original submission will result in the Offerors' elimination from further consideration. The LHC plans to award a single, incrementally funded, cost-reimbursement, level-of-effort, type contract for a four-year period with a required level-of-effort of 82,784 hours for all four years. The anticipated solicitation issue date is approximately 15 days after the publication of this notice, and proposals will be due approximately 30 days after the issue date. The RFP may be accessed through the Research Contracts Branch Home page by using the following Internet address: http://amb.nci.nih.gov/rfp.ht . IT IS THE OFFERORS RESPONSIBILITY TO MONITOR THE ABOVE INTERNET SITE FOR THE RELEASE OF THE SOLICITATION AND ANY AMENDMENTS. Point of contact is John R. Manouelian; electronic mail address: manouelj@mail.nih.gov; fax: 301-402-6699. Collect calls will NOT be accepted.

Web Link

Research Contracts Branch Home Page. (http://rcb.nci.nih.gov/)

Record

Loren Data Corp. 20001226/BSOL007.HTM (W-356 SN5094T0)